Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 17/20 | 0.45 |
| ▸ | NPY4R | P50391 | 3/20 | 0.41 |
| ▸ | NPFFR1 | Q9GZQ6 | 3/20 | 0.38 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31652448 | 0.94 | NPY1R (0.45) | NPY1RNPY4RNPFFR1NPY5R | |
| SCHEMBL31652910 | 0.94 | NPY1R (0.45) | NPY1RNPY4RNPFFR1NPY5R | |
| SCHEMBL31652727 | 0.92 | NPY1R (0.40) | NPY1RNPY4RNPFFR1NPY5R | |
| SCHEMBL31652634 | 0.91 | NPY1R (0.39) | NPY1RNPY4RNPFFR1NPY5R | |
| SCHEMBL31652731 | 0.91 | NPY1R (0.39) | NPY1RNPY4RNPFFR1NPY5R | |
| SCHEMBL31652828 | 0.90 | NPY1R (0.40) | NPY1RNPY4RNPFFR1NPY5R | |
| SCHEMBL31652935 | 0.89 | NPY1R (0.43) | NPY1RNPY4RNPFFR1 | |
| SCHEMBL31652831 | 0.87 | NPY1R (0.41) | NPY1RNPY4RNPFFR1NPFFR2NPY5R | |
| SCHEMBL31652538 | 0.87 | CXCR3 (0.38) | NPY1RNPY4R | |
| SCHEMBL31652858 | 0.85 | NPY4R (0.39) | NPY1RNPY4RNPFFR1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | NPY1R 1/4885NPY4R 3/4885NPFFR1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.